
ELV Stock Forecast & Price Target
ELV Analyst Ratings
Bulls say
Elevance Health is favored because its 3Q26 outperformance and raised FY26 adjusted EPS guidance to at least $29.00 suggest stronger underlying earnings power, while management also reaffirmed at least 12% EPS growth in 2027. The company’s scale in employer, individual, and government-sponsored coverage, plus its unique Blue Cross Blue Shield position across 14 states and expanded Medicaid and Medicare Advantage footprint through acquisitions, supports durable membership depth and pricing leverage. Improving Medicaid margins from a trough-like 2026, at least 2% Medicare Advantage operating margin, stronger ACA retention, and Carelon’s growing contribution in PBM and services all point to a broadening, more resilient earnings mix.
Bears say
Elevance Health is pressured by material regulatory and underwriting risks that cloud earnings visibility, including about $669 million of IDR liabilities under the No Surprises Act and another $324 million of unresolved exposure, with 94% tied to ASO business and outcomes still dependent on regulatory and litigation developments. Its core government lines also face headwinds from Medicare Advantage reimbursement risk, Medicaid redeterminations, and potential ACA exchange deterioration, while PBM earnings from IngenioRx, which contribute about 20% of total company earnings, remain exposed to drug-pricing and transparency reforms. Compounding these issues, management has lowered target operating margins to 5.0%–6.0%, signaling weaker profitability as care trend uncertainty, slower membership growth, and integration risk from acquisitions weigh on fundamentals.
This aggregate rating is based on analysts' research of Elevance Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELV Analyst Forecast & Price Prediction
Start investing in ELV
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Elevance Health Inc (ELV) Forecast
ELV Analyst Forecast & Price Prediction
Start investing in ELV
Order type
Buy in
Order amount
Est. shares
0 shares